• Maiden Half Year Profit after income tax of $1.1 million
• Profitability turnaround driven by product sales into pharmaceutical manufacturing market
• Growing pipeline of large global pharmaceutical companies supports confidence in sales outlook

Clever Culture Systems Ltd (ASX: CC5), a leader in microbiology automation using artificial intelligence, has reported a Profit after income tax of $1.1 million for the six months ending 31 December 2024, compared to a loss of $1.8 million in the prior corresponding period. This turnaround in profitability is a result of an increase in sales to $3.8 million, driven by the company's pivot to the pharmaceutical industry with six instrument sales completed. Following the half-year, a fifth instrument has been installed to AstraZeneca, and the company has received an additional order from AstraZeneca for a further four instruments. This strong commercial momentum has positioned the company to achieve or exceed cashflow breakeven in the second half of financial year 2025. The company has also further invested in R&D to expand the utility of the APAS® technology for its pharmaceutical customers, developing a new APAS® analysis module for 55mm contact plates to increase the market opportunity. The company is well-positioned to capitalize on its early achievements in the pharmaceutical market and remains committed to delivering continued commercial success while maintaining a disciplined approach to cost management.

The company expects to achieve or exceed cashflow breakeven in the second half of financial year 2025.

The company will increase its sales and marketing efforts in the pharmaceutical market, attending more global conferences and generating new publications. Large pharmaceutical manufacturing customers will continue to be a focus as they present significant multi-instrument sales opportunities. Completing the development of the contact plates application will further enhance the utility of APAS® Independence for the company's pharmaceutical customers.